Published in Gene Therapy Weekly, February 1st, 2001
"Current anti-HIV therapies targeting reverse transcriptase and protease enzymes suffer from high cost, a high probability of engendering resistance, and adverse side effects following prolonged use," explained O.M.Z. Howard and colleagues at the U.S. National Cancer Institute in Maryland. "Thus, we are faced with the need to develop new antiviral strategies with more potent compounds and/or novel antiviral targets."
The success of other...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.